Metformin as a Tool to Target Aging.
Level 5 - mechanism / opinion, no new human data
Narrative review/commentary proposing the rationale for metformin in aging and the TAME trial
PubMed 27304507 · doi:10.1016/j.cmet.2016.05.011
What was done
This is a narrative review discussing the targeting of aging via genetic, dietary, and pharmacological interventions, focusing on metformin and introducing the rationale for the planned Targeting Aging with Metformin (TAME) clinical trial.
What was found
The abstract reports no numerical data or primary findings. It notes qualitatively that metformin has demonstrated protective effects against several age-related diseases in humans and describes its planned evaluation in the TAME trial.
Why it matters
It outlines the framework for treating aging directly with metformin to extend healthspan and prevent multiple age-related chronic diseases simultaneously.
Limits
The abstract contains no primary clinical or experimental data, quantitative outcomes, or systematic review methodology. It represents expert commentary and the rationale for a planned study.
Cited by
- supports Nir Barzilai and colleagues are engaged in discussions with the FDA regarding advancing metformin as an anti-aging therapeutic candidate.